Mesenchymal stem/stromal cell therapy in atopic dermatitis and chronic urticaria: immunological and clinical viewpoints

Kim, Eun Young; Kim, Hyuk Soon; Hong, Ki-Sung; Chung, Hyung-Min; Park, Se-Pill; Noh, Geunwoong

doi:10.1186/s13287-021-02583-4

Cited by 7 publications

(5 citation statements)

References 155 publications

(207 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Specifically, MSC therapy offers an attractive substitute for immune disorder treatments, including those of relapsing or refractory types ( 47 ). The effects of MSCs in AD are well reviewed by Kim et al ( 48 ); Th2 polarization shift, decrease in IgE levels, allergen-specific Tregs elevation, Th2 cytokine downregulation, and eosinophil level reduction. Similar to reported immunomodulatory MSC effects, we successfully demonstrated that cAT-MSCs reduced eosinophil, IgE, and PEG2 levels, and elevated the percentage of Tregs in an experimental canine DFE ointment-induced AD model.…”

Section: Discussionmentioning

confidence: 99%

Immunomodulatory effects of canine mesenchymal stem cells in an experimental atopic dermatitis model

Kang

Byeon

et al. 2023

Front. Vet. Sci.

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) have the potential to differentiate into multi-lineage cells, suggesting their future applicability in regenerative medicine and biotechnology. The immunomodulatory properties of MSCs make them a promising replacement therapy in various fields of animal research including in canine atopic dermatitis (AD), a skin disease with 10–15% prevalence. We investigated the immunomodulatory effects of MSCs in an experimental canine AD model induced by Dermatophagoides farinae extract ointment. Canine adipose tissue-derived MSCs (cAT-MSCs) were differentiated into mesodermal cell lineages at the third passage. Alterations in immunomodulatory factors in control, AD, and MSC-treated AD groups were evaluated using flow cytometric analysis, enzyme-linked immunosorbent assay, and quantitative reverse transcription PCR. In the MSC-treated AD group, the number of eosinophils decreased, and the number of regulatory T cells (Tregs) increased compared to those in the AD group. In addition, the immunoglobulin E (IgE) and prostaglandin E2 levels were reduced in the MSC-treated AD group compared to those in the AD group. Furthermore, the filaggrin, vascular endothelial growth factor, and interleukin-5 gene expression levels were relatively higher in the MSC-treated AD group than in the AD group, however, not significantly. cAT-MSCs exerted immunomodulatory effects in an AD canine model via a rebalancing of type-1 and -2 T helper cells that correlated with increased levels of Tregs, IgE, and various cytokines.

show abstract

Section: Discussionmentioning

confidence: 99%

Immunomodulatory effects of canine mesenchymal stem cells in an experimental atopic dermatitis model

Kang

Byeon

et al. 2023

Front. Vet. Sci.

View full text Add to dashboard Cite

show abstract

“…Given the immunoregulatory and anti-inflammatory function [ 19 ], EVs from MSCs could be an alternative that can replace the current therapeutic protocol for AD [ 66 ]. Indeed, it was demonstrated that EVs from adipose-derived stem cells (ADSCs) could alleviate AD by reducing serum IgE, infiltration of inflammatory cells, and inflammatory cytokines.…”

Section: Discussionmentioning

confidence: 99%

Extracellular vesicles from IFN-γ-primed mesenchymal stem cells repress atopic dermatitis in mice

Kim¹,

Lee²,

Jung³

et al. 2022

J Nanobiotechnol

View full text Add to dashboard Cite

Background Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by immune dysregulation, pruritus, and abnormal epidermal barrier function. Compared with conventional mesenchymal stem cell (MSC), induced pluripotent stem cell (iPSC)-derived mesenchymal stem cell (iMSC) is recognized as a unique source for producing extracellular vesicles (EVs) because it can be obtained in a scalable manner with an enhanced homogeneity. Stimulation of iMSCs with inflammatory cytokines can improve the immune-regulatory, anti-inflammatory, and tissue-repairing potential of iMSC-derived EVs. Results Proteome analysis showed that IFN-γ-iMSC-EVs are enriched with protein sets that are involved in regulating interferon responses and inflammatory pathways. In AD mice, expression of interleukin receptors for Th2 cytokines (IL-4Rα/13Rα1/31Rα) and activation of their corresponding intracellular signaling molecules was reduced. IFN-γ-iMSC-EVs decreased itching, which was supported by reduced inflammatory cell infiltration and mast cells in AD mouse skin; reduced IgE receptor expression and thymic stromal lymphopoietin and NF-kB activation; and recovered impaired skin barrier, as evidenced by upregulation of key genes of epidermal differentiation and lipid synthesis. Conclusions IFN-γ-iMSC-EVs inhibit Th2-induced immune responses, suppress inflammation, and facilitate skin barrier restoration, contributing to AD improvement.

show abstract

“…Although this form of treatment looks promising, trials are new, and the chances of success are still low. But if it is successful, it may appear more frequently in the future as a radical and preventive treatment option [17].…”

Section: New Developments In Diagnosis and Therapy Of Allergic Diseasesmentioning

confidence: 99%

Introductory Chapter: Allergic Disease – New Developments in Diagnosis and Therapy

Özdemir¹

2023

Allergic Disease - New Developments in Diagnosis and Therapy

View full text Add to dashboard Cite

Mesenchymal stem/stromal cell therapy in atopic dermatitis and chronic urticaria: immunological and clinical viewpoints

Cited by 7 publications

References 155 publications

Immunomodulatory effects of canine mesenchymal stem cells in an experimental atopic dermatitis model

Immunomodulatory effects of canine mesenchymal stem cells in an experimental atopic dermatitis model

Extracellular vesicles from IFN-γ-primed mesenchymal stem cells repress atopic dermatitis in mice

Introductory Chapter: Allergic Disease – New Developments in Diagnosis and Therapy

Contact Info

Product

Resources

About